Gambro/Baxter split
This article was originally published in The Gray Sheet
Executive Summary
Joint venture will expire this year, with a shared Mountain Home, Ark. dialyzer production facility reverting solely to Baxter production. Gambro also will shut plants in Germany and Japan. All three facilities produce non-synthetic dialyzers, for which less capacity is needed given a market shift to biocompatible synthetic machines, Gambro explains. The firm notes that increased synthetic production at a German plant will offset the closures...
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.